Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Limentani

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Breast Cancer Research and Treatment|March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumorsSteven A Limentani, Mario Campone, Thierry Dorval, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Breast (Edinburgh, Scotland)|March 10, 2015
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized studyVéronique Diéras, Hans Wildiers, Jacek Jassem, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Breast Cancer Research and Treatment|March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumorsSteven A Limentani, Mario Campone, Thierry Dorval, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Breast (Edinburgh, Scotland)|March 10, 2015
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized studyVéronique Diéras, Hans Wildiers, Jacek Jassem, et al.
Pageof 5